tofacitinib etocomil (MH004) / Minghui Pharma - LARVOL DELTA

A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo (clinicaltrials.gov) - P3 | N=405 | Recruiting | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Vitiligo

A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo (clinicaltrials.gov) - P3 | N=405 | Not yet recruiting | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

New P3 trial • Dermatology • Immunology • Vitiligo

Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=156 | Completed | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Vitiligo

A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P3 | N=375 | Completed | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=160 | Completed | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=156 | Active, not recruiting | Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

New P2 trial • Dermatology • Immunology • Vitiligo

Minghui raises $131M 'pre-IPO' round to bankroll JAK inhibitor launch, ADC trials (FierceBiotech) - "Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential launch of its dermatitis cream in China as well as various clinical-stage oncology and immunology assets...The Shanghai-based biotech said part of the funds will be used to support a hoped-for commercial launch in China of MH004, a phase 3-stage pan-JAK inhibitor topical cream...Some of the fresh funds will also be used to push forward with Minghui’s various clinical programs, including a PD-1/VEGF bispecific antibody called MHB039A and a TROP-2-directed antibody-drug conjugate dubbed MHB036C....There’s also a B7-H3-targeted ADC called MHB088C."

Financing • Atopic Dermatitis • Castration-Resistant Prostate Cancer • Dermatitis • Non Small Cell Lung Cancer

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT (BioSpace) - "'The Phase 2 result is very impressive. MH004 Cream is a revolutionary product that represents an exciting advancement in topical therapies.' said Dr. Kim Papp..."

Media quote